Primary insulin-like growth factor-1 (IGF-1) deficiency
ICD-10 E34.321 is a billable code used to indicate a diagnosis of primary insulin-like growth factor-1 (igf-1) deficiency.
Primary insulin-like growth factor-1 (IGF-1) deficiency is a rare endocrine disorder characterized by insufficient levels of IGF-1, a hormone crucial for growth and development. This condition can lead to significant growth abnormalities, particularly in children, manifesting as short stature and delayed puberty. IGF-1 is primarily produced in the liver and its secretion is stimulated by growth hormone (GH). Deficiency can arise from various causes, including genetic mutations affecting the GH-IGF-1 axis, malnutrition, or other underlying endocrine disorders. Patients may present with symptoms such as reduced growth velocity, delayed skeletal maturation, and other associated endocrine dysfunctions. The diagnosis is typically confirmed through serum IGF-1 levels, alongside clinical evaluation and family history. Management may involve GH therapy, nutritional support, and monitoring for associated conditions such as polyglandular autoimmune syndromes or thymus disorders, which can complicate the clinical picture.
Growth charts, IGF-1 serum levels, and detailed patient history.
Evaluation of short stature in children, assessment of delayed puberty.
Consideration of familial patterns and genetic testing may be necessary.
Comprehensive endocrine evaluation, including hormone levels and imaging studies.
Management of growth hormone therapy, monitoring for side effects.
Need to assess for other endocrine disorders that may coexist.
Used to confirm diagnosis of IGF-1 deficiency.
Document the reason for testing and results.
Endocrinologists should ensure comprehensive evaluation of growth patterns.
Common symptoms include short stature, delayed puberty, and reduced growth velocity. Patients may also experience psychosocial issues related to their growth.
